Sai Parenterals to Acquire Majority Stake in Bion Therapeutics India Through SP Analytics Subsidiary by November 30, 2026
Acquisition funded via IPO proceeds and debt to broaden Sai Parenterals’ pharmaceutical portfolio with Bion becoming a step-down subsidiary
Sai Parenterals Limited, via its wholly owned subsidiary SP Analytics Private Limited, will acquire a majority stake in Hyderabad-based Bion Therapeutics India Private Limited in an all-cash transaction expected to complete by November 30, 2026. The acquisition supports expansion into branded formulations prescription business with Bion becoming a step-down subsidiary.
Sai Parenterals Limited
Acquisition / Amalgamation / Merger / Demerger
Sai Parenterals Limited announced that its wholly owned subsidiary, SP Analytics Private Limited, will acquire a majority stake in Hyderabad-based Bion Therapeutics India Private Limited in an all-cash transaction expected to close by November 30, 2026.
The Board of Sai Parenterals approved the signing of the acquisition agreement, making Bion Therapeutics a step-down subsidiary upon completion.
The deal will be funded by a combination of proceeds earmarked for General Corporate Purposes from the Company's IPO and additional debt, subject to legal approvals.
Bion Therapeutics operates in the pharmaceutical sector focusing on branded formulations prescription business and reported a turnover of Rs. 28.22 crore for the half-year ended September 30, 2026.
The acquisition is being conducted on an arm's-length basis following independent valuation and complies with relevant regulatory and related party transaction provisions.
Bion Therapeutics was incorporated in 2005 and has shown consistent income with Rs. 47.29 crore reported in FY 2025-26.
Highlights
- Acquisition to be completed on or before November 30, 2026.
- Transaction is an all-cash deal funded through IPO proceeds and debt.
- Bion Therapeutics had a turnover of Rs. 28.22 crore in H1 FY 2026-27.
- Bion will become a step-down subsidiary post acquisition.
- Acquisition conducted on arm's-length basis with independent valuation.
Key Data Snapshot
What happened
- Sai Parenterals Limited’s Board approved acquisition of majority stake in Bion Therapeutics India Private Limited via its wholly owned subsidiary SP Analytics Private Limited.
- The transaction is an all-cash deal expected to complete on or before November 30, 2026, making Bion a step-down subsidiary of Sai Parenterals.
- Funding support will come from the Company’s IPO proceeds earmarked for general corporate purposes and debt, pending requisite approvals.
Key details
- Bion Therapeutics is based in Hyderabad and operates in the branded formulations prescription pharma segment.
- Turnover reported by Bion was Rs. 28.22 crore for the half-year ended September 30, 2026, with consistent income over the past three fiscal years.
- The acquisition will be executed on an arm's-length basis following independent valuation.
- No governmental or regulatory approvals are required for this acquisition.
Transaction details
- Acquisition involves majority stake and/or controlling interest in Bion Therapeutics India Private Limited.
- The acquisition price is based on independent valuation; the transaction consideration is cash-only.
- Bion was incorporated on September 5, 2005, primarily for pharmaceutical testing and formulations business.
Funding and capital details
- Necessary funding to SP Analytics Private Limited will utilize proceeds from Sai Parenterals Limited’s IPO earmarked for General Corporate Purposes and debt.
- All financial support and acquisition funding will comply with applicable laws and require necessary approvals.
Highlights
- Acquisition to be completed on or before November 30, 2026.
- Transaction is an all-cash deal funded through IPO proceeds and debt.
- Bion Therapeutics had a turnover of Rs. 28.22 crore in H1 FY 2026-27.
- Bion will become a step-down subsidiary post acquisition.
- Acquisition conducted on arm's-length basis with independent valuation.
Disclosures
- Companies Act, 2013
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The acquisition is by company's wholly owned subsidiary; potential interests of promoters or selling shareholders to be disclosed as applicable.
More News on Acquisition / Amalgamation / Merger / Demerger
View allLatest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.
Apollo Micro Systems' Subsidiary Commits to Acquire 26% Stake in A-Thon Allterrain, Expanding into Defence Land Systems
Apollo Defence Industries, a subsidiary of Apollo Micro Systems Limited, has executed a binding expression of interest to acquire up to 26% equity in A-Thon Allterrain Private Limited, marking Apollo's strategic expansion into the defence land systems sector.
Read Full StoryMotion JVCo Limited Initiates 26% Stake Acquisition in Castrol India Limited via INR 199.45 Open Offer
Motion JVCo Limited and its partner entities have launched an open offer to acquire up to 25,71,71,820 equity shares, representing 26% of Castrol India Limited, at an offer price of INR 199.45 per share. The offer commenced on December 24, 2026 and will close on January 7, 2027.
Read Full StoryBlackRock Surpasses 5% Ownership in Axis Bank Ltd After November 2026 Market Purchase
BlackRock, Inc., on behalf of discretionary management clients, increased its shareholding in Axis Bank Ltd to 5.00% following an on-market share purchase executed on 13 November 2026, triggering a mandatory disclosure under SEBI regulations.
Read Full Story